SPR Therapeutics LOGO 361 TM.jpg
Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS
17 mai 2023 10h16 HE | SPR Therapeutics, Inc.
CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant...
SPR Therapeutics LOGO 361 TM.jpg
SelectHealth Initiates Peripheral Nerve Stimulation (PNS) Coverage to Support Patient Need for Effective Non-opioid Pain Treatment
04 mai 2023 11h07 HE | SPR Therapeutics, Inc.
CLEVELAND, May 04, 2023 (GLOBE NEWSWIRE) -- SelectHealth, a non-profit health plan with over one million members, has demonstrated leadership amid the opioid crisis by creating one of the first...
SPR Therapeutics LOGO 361 TM.jpg
New SPRINT extensa XT™ System with Bimodal PNS™ Offers Synergistic Treatment of Pain
25 avr. 2023 10h00 HE | SPR Therapeutics, Inc.
CLEVELAND, Ohio, April 25, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference
16 mars 2023 08h00 HE | SPR Therapeutics, Inc.
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients suffering from acute or...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
03 févr. 2023 15h32 HE | SPR Therapeutics, Inc.
CLEVELAND, Feb. 03, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022
17 nov. 2022 09h00 HE | SPR Therapeutics, Inc.
CLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At the 21st Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in Orlando, SPR Therapeutics is highlighting five new data sets...
SPR Therapeutics LOGO 361 TM.jpg
Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves
21 sept. 2022 15h02 HE | SPR Therapeutics, Inc.
- Data presented at Pacific Spine Pain Society annual meeting - CLEVELAND, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics shared data on the use of peripheral nerve stimulation (PNS) to...
ML2pt0_strengthimage_press_v1
Next Generation MicroLead 2.0 Now Available with the SPRINT® PNS System
06 sept. 2022 08h00 HE | SPR Therapeutics, Inc.
CLEVELAND, Sept. 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today the formal introduction of its new MicroLead™ 2.0, designed to enhance the performance of the SPRINT® PNS System. As a...
SPR Therapeutics LOGO 361 TM.jpg
Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs
02 août 2022 16h23 HE | SPR Therapeutics, Inc.
CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs. In this role, he will provide...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
14 juil. 2022 10h54 HE | SPR Therapeutics, Inc.
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of...